PDCD1 and classic Hodgkin lymphoma: Even in the modern era of managing r/r cHL with the ability to obtain prolonged remissions and disease control with novel agents such as BV and anti-PD-1 therapies, there will still remain a small group of highly refractory patients for whom this is the only potentially curative option.